SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps
- PMID: 27177498
- DOI: 10.1016/j.ando.2016.02.003
SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps
Abstract
In patients with suspected primary aldosteronism (PA), the first diagnostic step, screening, must have high sensitivity and negative predictive value. The aldosterone-to-renin ratio (ARR) is used because it has higher sensitivity and lower variability than other measures (serum potassium, plasma aldosterone, urinary aldosterone). ARR is calculated from the plasma aldosterone (PA) and plasma renin activity (PRA) or direct plasma renin (DR) values. These measurements must be taken under standard conditions: in the morning, more than 2hours after awakening, in sitting position after 5 to 15minutes, with normal dietary salt intake, normal serum potassium level and without antihypertensive drugs significantly interfering with the renin-angiotensin-aldosterone system. To rule out ARR elevation due to very low renin values, ARR screening is applied only if aldosterone is>240pmol/l (90pg/ml); DR values<5mIU/l are assimilated to 5mIU/l and PRA values<0.2ng/ml/h to 0.2ng/ml/h. We propose threshold ARR values depending on the units used and a conversion factor (pg to mIU) for DR. If ARR exceeds threshold, PA should be suspected and exploration continued. If ARR is below threshold or if plasma aldosterone is<240pmol/l (90pg/ml) on two measurements, diagnosis of PA is excluded.
Keywords: Aldosterone; Aldosterone-to-renin ratio (ARR); Aldostérone; Conditions standardisées; Dépistage; Hyperaldostéronisme primaire; Primary aldosteronism; RAR; Rapport aldosterone/rénine; Renin; Rénine; Screening; Standard conditions.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.
Similar articles
-
SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing.Ann Endocrinol (Paris). 2016 Jul;77(3):202-7. doi: 10.1016/j.ando.2016.01.007. Epub 2016 Jun 16. Ann Endocrinol (Paris). 2016. PMID: 27318644
-
Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension.Ann Cardiol Angeiol (Paris). 2015 Jun;64(3):169-74. doi: 10.1016/j.ancard.2015.04.017. Epub 2015 Jun 4. Ann Cardiol Angeiol (Paris). 2015. PMID: 26051856
-
[Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients].Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Oct;34(10):868-72. Zhonghua Xin Xue Guan Bing Za Zhi. 2006. PMID: 17217708 Chinese.
-
SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.Ann Endocrinol (Paris). 2016 Jul;77(3):179-86. doi: 10.1016/j.ando.2016.05.001. Epub 2016 Jun 15. Ann Endocrinol (Paris). 2016. PMID: 27315757
-
Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism.Hypertens Res. 2010 Aug;33(8):850-6. doi: 10.1038/hr.2010.76. Epub 2010 Jun 3. Hypertens Res. 2010. PMID: 20520614
Cited by
-
Diagnostic Accuracy of Aldosterone and Renin Measurement by Chemiluminescence for Screening of Patients with Primary Aldosteronism.Int J Mol Sci. 2024 Aug 2;25(15):8453. doi: 10.3390/ijms25158453. Int J Mol Sci. 2024. PMID: 39126022 Free PMC article.
-
Endocrine causes of hypertension: literature review and practical approach.Hypertens Res. 2023 Dec;46(12):2679-2692. doi: 10.1038/s41440-023-01461-1. Epub 2023 Oct 11. Hypertens Res. 2023. PMID: 37821565 Review.
-
Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism.Endocrine. 2024 Jul;85(1):99-121. doi: 10.1007/s12020-024-03751-1. Epub 2024 Mar 6. Endocrine. 2024. PMID: 38448679 Review.
-
Evaluation of Predictive Risk Factors of Persistent Hypertension in Hyperaldosteronism After Surgery.Int J Endocrinol Metab. 2025 Apr 30;23(2):e156728. doi: 10.5812/ijem-156728. eCollection 2025 Apr 30. Int J Endocrinol Metab. 2025. PMID: 40726583 Free PMC article.
-
Familial hyperaldosteronism type III a novel case and review of literature.Rev Endocr Metab Disord. 2019 Mar;20(1):27-36. doi: 10.1007/s11154-018-9481-0. Rev Endocr Metab Disord. 2019. PMID: 30569443 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials